Please try another search
Oncolys BioPharma Inc. is a biopharmaceutical company. The Company operates in two business segments. Pharmaceutical business segment is engaged in the research, development, manufacture and marketing of pharmaceuticals. Diagnostic reagents business segment is engaged in the research, development, manufacture and marketing of diagnostic reagents and equipment, as well as the provision of inspection service. The Company's main pipeline includes OBP-301 (Telomelysin), an oncolytic virus; OBP-801, an epigenetic anticancer drug and OBP-601 for the treatment of human immunodeficiency virus (HIV) infection, among others.
Name | Age | Since | Title |
---|---|---|---|
Yasuo Urata | 66 | 2004 | CEO, President & Representative Director |
Katsufusa Tachiya | - | 2017 | Corporate Auditor |
Shiro Ohki | 80 | 2011 | External Auditor |
Yoshitomo Nagatsuka | 58 | 2021 | Outside Auditor |
Naoko Iino | 64 | 2023 | Independent Outside Director |
Keiji Yoshimura | 69 | 2013 | Director of Finance & Accounting, Business and Risk Management and Director |
Toru Saito | 67 | 2022 | Independent External Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review